Volume 10, Issue 3 (Summer 2021)                   J Occup Health Epidemiol 2021, 10(3): 169-174 | Back to browse issues page


XML Print


1- Msc in Parasitology, Social Determinants in Health Promotion Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
2- Msc in Microbiology, Social Determinants in Health Promotion Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
3- PhD Student in Epidemiology, Social Determinants in Health Promotion Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
4- Associate Prof., Social Determinants in Health Promotion Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
5- Professor, Dept. of Medical Entomology and Vector Control, School of Health, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
6- Assistant Prof., Social Determinants in Health Promotion Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
7- Associate Prof., Dept. of Medical Entomology and Vector Control, School of Health, Hormozgan University of Medical Sciences, Bandar Abbas, Iran. , Alireza.sanee@gmail.com
Article history
Received: 2021/09/26
Accepted: 2021/11/6
ePublished: 2021/12/1
Subject: Epidemiology
Abstract:   (1193 Views)

Background: According to recent reports during the COVID-19 pandemic, malaria-endemic regions have a significantly lower COVID-19 case and mortality rate than those malaria-non-endemic.  This study aimed to evaluate the prevalence of COVID-19 in malarious areas of southern Iran and the incidence of disease in people previously infected with malaria.
Materials and Methods: We conducted an ecological study during the Covid-19 epidemic period in a malaria-endemic area, Hormozgan province, by including all critically ill patients with Covid-19 admitted to hospitals in different counties. The malaria cases were matched in the Covid patient's list. Also, the cumulative incidence and mortality rate of the Covid-19 were calculated in all counties.
Results: The results show that malaria-endemic regions have a lower cumulative incidence and mortality rate than the others. Moreover, it was found that people with a history of malaria were not infected with Covid 19.
Conclusion: It seems that malaria endemicity may positively affect the lower incidence and mortality rate of COVID-19 in malaria-endemic regions. However, further studies must be carried out to confirm the hypothesis that malaria reduces the risk of Covid-19 in other parts of the world.

Keywords: COVID-19 [MeSH], Malaria [MeSH], Iran [MeSH]
Full-Text [PDF 682 kb]   (589 Downloads) |   |   Full-Text (HTML)  (279 Views)  

References
1. World Health Organization. Coronavirus disease 2019 (COVID-19): situation report, 82. Geneva, Switzerland: World Health Organization; 2020. [Report]
2. Lawal Y. Africa’s low COVID-19 mortality rate: A paradox? Int J Infect Dis 2021; 102:118-22. [DOI] [PMID] [PMCID]
3. World Health Organization. World Malaria Report 2020: Geneva, Switzerland: World Health Organization; 2020. [Report]
4. Worldometers. COVID-19 Coronavirus Pandemic: Reported Cases and Deaths by Country. 2021 Feb 20. Available from: https://www.worldometers.info/coronavirus/#countries
5. Worldometers. World Population by Country. 2021 Feb 20. Available from: https://www.worldometers.info/world-population/population-by-country/
6. Bosso M, Thanaraj TA, Abu-Farha M, Alanbaei M, Abubaker J, Al-Mulla F. The Two Faces of ACE2: The Role of ACE2 Receptor and Its Polymorphisms in Hypertension and COVID-19. Mol Ther Methods Clin Dev 2020; 18:321-7. [DOI] [PMID] [PMCID]
7. Parodi A, Cozzani E. Coronavirus disease 2019 (COVID 19) and Malaria. Have anti glycoprotein antibodies a role? Med Hypotheses 2020; 143:110036. [DOI] [PMID] [PMCID]
8. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020; 14(1):72-3. [DOI] [PMID]
9. Shah S, Das S, Jain A, Misra DP, Negi VS. A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease‐19 (COVID‐19). Int J Rheum Dis 2020; 23(5):613-9. [DOI] [PMID] [PMCID]
10. Raeisi A, Gouya MM, Nadim A, Ranjbar M, Hasanzehi A, Fallahnezhad M, et al. Determination of Malaria Epidemiological Status in Iran’s Malarious Areas as Baseline Information for Implementation of Malaria Elimination Program in Iran. Iran J Public Health 2013; 42(3):326-33. [Article]
11. Vatandoost H, Raeisi A, Saghafipour A, Nikpour F, Nejati J. Malaria situation in Iran: 2002–2017. Malar J 2019; 18(1):200. [DOI] [PMID] [PMCID]
12. Azizi H, Davtalab-Esmaeili E, Farahbakhsh M, Zeinolabedini M, Mirzaei Y, Mirzapour M. Malaria situation in a clear area of Iran: an approach for the better understanding of the health service providers’ readiness and challenges for malaria elimination in clear areas. Malar J 2020; 19(1):114. [DOI] [PMID] [PMCID]
13. Sanei-Dehkordi A, Soleimani-Ahmadi M, Jaberhashemi SA, Zare M. Species composition, seasonal abundance and distribution of potential anopheline vectors in a malaria endemic area of Iran: field assessment for malaria elimination. Malar J 2019; 18(1):157. [DOI] [PMID] [PMCID]
14. Zare M, Soleimani-Ahmadi M, Davoodi SH, Sanei-Dehkordi A. Insecticide susceptibility of Anopheles stephensi to DDT and current insecticides in an elimination area in Iran. Parasit Vectors 2016; 9(1):571. [DOI] [PMID] [PMCID]
15. Ghahremani L, Azizi M, Moemenbellah-Fard MD, Ghaem H. Malaria preventive behaviors among housewives in suburbs of Bandar-Abbas City, south of Iran: interventional design based on PRECEDE model. Pathog Glob Health 2019; 113(1):32-8. [DOI] [PMID] [PMCID]
16. Lestari K, Sitorus T, Instiaty, Megantara S, Levita J. Molecular Docking of Quinine, Chloroquine and Hydroxychloroquine to Angiotensin Converting Enzyme 2 (ACE2) Receptor for Discovering New Potential COVID-19 Antidote. J Adv Pharm Educ Res 2020; 10(2):1-4. [Article]
17. Li G, Yuan M, Li H, Deng C, Wang Q, Tang Y, et al. Safety and efficacy of artemisinin-piperaquine for treatment of COVID-19: an open-label, non-randomised and controlled trial. Int J Antimicrob Agents 2021; 57(1):106216. [DOI] [PMID] [PMCID]

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.